Buy Sibelium (Flunarizine 5/10mg) Online - Calcium Channel Blocker for Migraine Prophylaxis and Vertigo

Sibelium is a brand name for flunarizine dihydrochloride, a selective calcium channel blocker with additional antihistamine properties. Unlike triptans or NSAIDs, flunarizine is not used to stop a migraine attack in progress. It is taken daily as a preventive medication — a drug that reduces how often attacks happen rather than treating individual attacks.

Flunarizine acts primarily by blocking calcium entry into vascular smooth muscle and neurons. The result is stabilization of cerebral blood vessels and reduced neuronal hyperexcitability. The exact mechanism in migraine prevention is not fully understood, but trials consistently show significant reduction in attack frequency over 2-3 months of daily use in appropriate patients.

Flunarizine fits a specific place in migraine care. It is not for every patient and not for every situation. Understanding when it fits well — and when it does not — helps patients and prescribers decide whether a Sibelium trial makes sense or whether a different preventive would be a better choice.

The global availability of flunarizine varies — it is widely used in Europe, Asia, Latin America, and Canada but has never been approved in the United States. US patients considering flunarizine often access it through international pharmacies. The lack of US approval reflects regulatory history rather than efficacy concerns; the drug is well-studied in migraine prevention.

Flunarizine is typically prescribed when migraine attack frequency has become disruptive enough that daily preventive therapy is warranted and other first-line preventives have been tried or ruled out. The decision to start Sibelium is a thoughtful one — the drug requires commitment to daily dosing for weeks before any benefit appears, and side effects demand monitoring throughout.

The decision to start flunarizine deserves a dedicated conversation. It is not a drug to try casually or add quickly to a regimen. The side-effect burden is real; the time commitment is long; the follow-up requirements are specific. Patients who start with full understanding of what the drug asks of them are more likely to complete a successful trial and reach meaningful attack reduction.

Flunarizine has multiple pharmacological actions — which is both why it works in several conditions (migraine, vertigo, vascular disease) and why it has a wider side-effect profile than more selective drugs. Understanding the mechanisms helps explain both the benefits and the risks that patients experience.

The calcium channel blockade is the main migraine prevention mechanism, but flunarizine is selective for cerebral vessels rather than cardiac muscle — which is why it does not cause the heart rate or blood pressure effects of other calcium channel blockers like verapamil or diltiazem. This cerebrovascular selectivity makes it tolerable in patients without cardiovascular disease but does not eliminate the risks related to its other actions.

The very long half-life — approximately 18-19 days — has important practical implications. The drug accumulates slowly over 2-3 months to reach steady state (the biological reason the full migraine benefit takes months to appear). After discontinuation, the drug clears equally slowly — residual effects can persist for weeks. This matters for timing changes and for side-effect resolution.

Standard flunarizine dosing is 5 mg or 10 mg once daily, taken in the evening. The 10 mg dose is the usual target for adults; the 5 mg dose is often used in older patients, lighter patients, and when side effects are a concern. Evening dosing is strongly preferred because the sedating effect that appears within hours works with sleep rather than against daytime function.

Older patients and pediatric patients deserve specific dosing attention. Patients over 65 should start and often stay at 5 mg, with careful monitoring for extrapyramidal effects. Children aged 10-16 can usually use 5 mg; children under 10 are generally not candidates for flunarizine. Dose adjustments based on body weight and tolerability are more individualized than in standard adult practice.

The timeline of flunarizine's migraine benefit is one of the most important things for patients to understand. Unlike acute abortives that work in minutes, flunarizine takes weeks to months to show full effect. Patients who do not know this often stop too early, concluding the drug does not work when they simply have not given it enough time to accumulate and act.

The 12-week assessment point is where the migraine prevention effect should be clearly measurable. Before that, interim improvements may or may not be meaningful; after that, the pattern becomes clear enough to make continuation decisions. Patients who respond typically show 30-50% reduction in attack frequency compared with baseline by the 3-month mark.

Measuring success requires comparing monthly attack frequency before starting to monthly attack frequency after 3 months. Without a baseline count, there is no way to know if the drug helped. This is why keeping a diary before starting flunarizine is important — usually 1-2 months of baseline data provides the comparison needed to make an informed continuation decision.

Flunarizine treatment is traditionally limited to 6 months of continuous use, after which a treatment break is required. This limit exists specifically because the dopamine-related side effects — extrapyramidal symptoms, depression, galactorrhea — accumulate with longer exposure. Six months of continuous use is the balance point between adequate therapeutic benefit and manageable long-term risk.

The taper at month 6 is usually straightforward because the drug's long half-life creates its own gradual decline. Patients often simply stop the daily dose and let the plasma level fall over the subsequent 6-8 weeks. Some protocols include a formal taper (10 mg to 5 mg for 2-4 weeks, then stop); others use abrupt discontinuation. The long half-life makes either approach acceptable.

Patients who respond well without side effects and who return to baseline migraine frequency during the break can usually restart safely. The restarted course is similarly limited to 6 months. Over multiple cycles, cumulative exposure matters — patients who have used flunarizine for multiple 6-month courses over several years should discuss alternative long-term preventives with their prescriber.

Measuring whether flunarizine is working is more involved than measuring an acute drug's effect. The outcome is reduced attack frequency over months, not relief of a single attack. Reliable measurement requires baseline data, consistent tracking during treatment, and realistic benchmarks for what counts as success.

The 50% response threshold is the standard benchmark in migraine prevention trials. A patient whose attack frequency drops at or over 50% is a clear responder — the drug is clearly worth continuing (within the 6-month limit). A patient with 30-49% reduction is a partial responder — the drug helps but the benefit may not justify side effects. A patient with under 30% reduction after a full 12-week trial is probably not responding meaningfully.

A migraine diary serves two specific functions during flunarizine treatment: establishing the baseline against which to measure benefit, and tracking side-effect patterns that can shift the risk-benefit calculation. Diary entries during the first 3 months of treatment are the single most useful data for the week-12 continuation decision.

The information worth capturing: monthly attack count, severity of each attack, duration, acute medication used, any aura or vestibular features, and the flunarizine-specific side-effect watchlist (sedation, weight, mood, movements). Brief notes beat elaborate ones — the diary is only useful if actually maintained.

Week of: Nov 10
Attacks this week: 1 (Tuesday, 6/10 severity, 4 hours)
Acute meds used: 1 dose rizatriptan
Daily flunarizine: taken all 7 nights
Sedation level: moderate first 2 hours after dose
Weight: 68.5 kg (up 0.5 kg from baseline)
Mood: stable, no low days
Movement check: no tremor, no stiffness, normal
Notes: slight restlessness evenings

Weekly rather than daily entries work well for most patients because flunarizine's effect is slow and cumulative. Daily tracking is often more detail than needed; weekly summaries capture the pattern without becoming burdensome. During the first 12 weeks, consistency matters more than detail — a brief weekly note maintained for 12 weeks is more valuable than detailed daily notes that stop at week 3.

Many patients find migraine-specific apps easier than paper diaries. Useful features: tracking by calendar day, trigger logging, medication count, severity rating, PDF export for doctor visits. For flunarizine specifically, apps that let you add a daily "preventive drug taken" box work well because adherence to the daily dose is a core element of success.

Flunarizine is not designed for continuous long-term use. The structure is 6-month cycles with mandatory breaks, with the possibility of restarting if migraines recur after the drug has fully cleared. Patients who have used flunarizine for multiple cycles need thoughtful long-term planning that considers cumulative dopaminergic exposure.

The alternatives at the long-term decision point include many well-tolerated options: CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) that are safer for long-term use than flunarizine; beta-blockers (propranolol, metoprolol); candesartan; topiramate; and neuromodulation devices (external or implantable). The modern preventive landscape has grown significantly, and patients who were started on flunarizine years ago may have better options now.

Patients should not feel pressured to restart flunarizine simply because the first cycle worked well. The purpose of the mandatory break is specifically to reassess whether continued use is wise. "It worked, so let us restart" is only one of several reasonable conclusions — "it worked, but we have learned enough about my pattern that we should try a different preventive with lower cumulative risk" is equally reasonable.

Lifestyle factors have a measurable impact on migraine attack frequency and work alongside flunarizine rather than instead of it. The combination of pharmacological prevention plus sustained lifestyle changes often reduces attack frequency more than either approach alone. During a flunarizine trial, maintaining consistent lifestyle practices also makes it easier to assess whether the drug is working — variability in sleep, hydration, and triggers is reduced.

The lifestyle approach is most powerful when combined rather than used in isolation. A patient on flunarizine who also addresses sleep consistency, hydration, meal timing, and one specific trigger often sees 60-70% total frequency reduction — much better than flunarizine alone (30-50%) or lifestyle alone (20-30%). The interventions compound.

Dehydration is one of the most common and easily correctable migraine triggers. Even mild dehydration can precipitate an attack in susceptible patients. Patients on flunarizine should take hydration seriously for two reasons: it prevents attacks that would break through the drug's prevention effect, and it offsets flunarizine-related dry mouth, a common minor side effect.

The target is consistent intake throughout the day, with urine color as a practical indicator (pale yellow is well-hydrated; dark yellow suggests underhydration). Patients who use the color check adjust their intake naturally and avoid both dehydration and excessive drinking.

Dietary triggers for migraine are highly individual. The classic culprits (red wine, aged cheese, chocolate, MSG, aspartame, nitrates) trigger attacks reliably in some patients and not at all in others. The only way to know yours is systematic observation and elimination testing. For flunarizine patients, dietary attention has a second purpose: mindful eating helps counter the drug's appetite-increasing effect.

The elimination testing approach: identify a suspect, eliminate it completely for 4 weeks, then reintroduce once and watch for attacks within 24 hours. Testing multiple suspects simultaneously makes it impossible to know which one was the real trigger — test one at a time, 4-6 weeks each.

The chocolate paradox deserves specific mention. Chocolate cravings often occur during the prodrome of a migraine attack — the body's attempt to raise serotonin precursors. Patients eating chocolate during the prodrome then interpret the subsequent attack as chocolate-triggered when the attack was already in progress.

For patients where the skipped meal pattern is confirmed as a migraine trigger, the fix is often simple: never skip breakfast; carry snacks; eat protein-plus-carb combinations that stabilize blood sugar. This single change prevents many attacks for patients whose attacks correlate with hunger or late meals — which is particularly valuable because flunarizine takes months to show full effect.

Migraine is an invisible disability. Partners, family members, employers, and friends often struggle to understand attack severity because migraine does not show on the outside. For flunarizine patients, communication serves two purposes: explaining migraine itself and explaining the side-effect profile that may affect daily life during the 6-month course — sedation, mood changes, weight shifts.

The core message to communicate: migraine is a neurological disease, not a bad headache or stress reaction. During an attack, bright lights, loud sounds, and demanding conversations are physically painful in a way healthy people do not experience. Rest in a dark quiet place is not avoidance — it is a medical necessity.

Many partners want to help but do not know how. A simple list of what helps and what does not help gives them something concrete. For flunarizine patients specifically, partners can help by: noticing mood changes early; supporting evening routine that accommodates sedation; encouraging exercise that counters weight gain; and flagging any new movement differences (tremor, stiffness, restlessness) the patient may not have noticed.

The emotional impact of chronic migraine on relationships is often underappreciated. Partners of migraine patients report significant quality-of-life effects of their own. Couples therapy sessions focused on chronic illness, or online support communities for migraine partners, can be valuable supplements to medical treatment. The migraine is a family issue, not just the patient's issue, and the dynamics around a preventive drug trial affect everyone in the household.

Migraine and anxiety have a bidirectional relationship, and both are relevant during a flunarizine trial for an important reason: flunarizine itself can precipitate or worsen depression through its dopamine-blocking activity. Mood monitoring is not optional on this drug — it is a core part of safe use.

Patients with severe depression or suicidal ideation during flunarizine use need emergency evaluation. This is not a situation for "waiting until the next appointment." Call the prescriber the same day, go to the emergency department if the ideation is immediate, and understand that the flunarizine will almost certainly need to stop as part of managing the acute mood issue.

Regular aerobic exercise is particularly valuable for flunarizine patients. It serves three distinct purposes: direct migraine prevention effect, counteracting the drug's weight-gain tendency, and supporting mood during a treatment with known depression risk. Patients who maintain regular exercise during their flunarizine course consistently report better overall experiences than those who do not.

The target intensity is moderate — conversation-pace, able to speak in short sentences but not sing. More intense exercise is not necessary and can sometimes trigger attacks in some patients. For flunarizine patients, morning or afternoon exercise is preferred over evening exercise — the evening sedation from the drug reduces motivation and alertness for workouts.

The weight-management benefit of exercise is particularly relevant on flunarizine. The drug's appetite-stimulating effect combined with its sedative effect creates a pattern where many patients gain 2-5 kg over the 6-month course. Regular exercise typically cuts this gain in half, which can be the difference between an acceptable side effect and one that leads to discontinuation.

Patients should not aim for weight loss during flunarizine — the biological pressure toward weight gain makes active weight loss unrealistically difficult. The realistic goal is weight maintenance or minimal gain through consistent exercise and mindful eating. Weight loss can be addressed after the 6-month flunarizine course when the biological driver is removed.

Identifying personal migraine triggers through systematic diary tracking complements flunarizine prevention nicely. The drug reduces frequency; trigger avoidance reduces it further. Together they can produce much better outcomes than either alone. Triggers are highly individual, and the only reliable way to find yours is sustained observation over 2-3 months.

Most patients discover 2-4 reliable triggers after disciplined diary tracking. Avoiding or managing those specific triggers often reduces attack frequency by 20-40% on top of whatever benefit the preventive medication provides. The categories to watch: dietary, hormonal, sleep-related, environmental, and stress-related triggers.

Weather-triggered migraines are common and frustrating because they cannot be avoided — only prepared for. Patients who track barometric pressure drops often find reliable patterns and can preemptively hydrate, rest, or use acute medication at the first signs when weather conditions align with their trigger pattern.

Patients with menstrual migraine deserve a specific plan. Attacks that cluster reliably around menstruation can often be managed with short-course prophylaxis around the expected attack period. Flunarizine's daily preventive effect does cover these attacks to some degree, but patients who still have significant perimenstrual breakthrough can discuss targeted strategies with the prescriber.

Sleep is the single most powerful lifestyle lever for migraine, and it combines particularly well with flunarizine for one practical reason: the drug's sedation effect aids sleep onset. The evening dose, taken 1-2 hours before bedtime, lines up with the natural circadian wind-down and often improves sleep quality for patients whose insomnia had been a migraine trigger.

The target remains 7-9 hours per night, at the same time each night (within 30 minutes), weekdays and weekends alike. The weekend sleep-in that feels like a reward is often the setup for a Sunday migraine. Patients who protect weekend sleep schedules often eliminate this specific pattern — and the consistent schedule works especially well on flunarizine because the drug supports stable sleep timing.

The Sunday morning migraine pattern — attack reliably on the first morning after a late Friday or Saturday night — is almost always caused by sleep schedule shift. Returning to a consistent weekday-like Sunday schedule, even if it means less overall sleep on Saturday night, eliminates this pattern for most affected patients. Flunarizine does not prevent sleep-schedule-triggered attacks; it provides a floor of prevention that lifestyle discipline builds on.

Sleep apnea deserves specific attention in migraine patients who snore, feel unrefreshed after full nights of sleep, or wake with headaches. Treating apnea often reduces migraine frequency independently of any medication change. A simple screening questionnaire or a formal sleep study resolves the question — and treating apnea during the flunarizine trial maximizes the chances of a successful outcome.

Flunarizine side effects fall into four main categories: sedation (very common and expected), weight gain (common and gradual), extrapyramidal symptoms (less common but potentially serious), and depression (less common but critically important). Understanding each category helps patients recognize issues early and distinguish expected effects from warning signs.

Most patients experience sedation and mild weight gain as the main side effects. These are usually manageable. The serious side effects — depression and extrapyramidal symptoms — are rarer but more concerning. Early recognition and prompt discontinuation almost always lead to full resolution; delayed recognition can lead to prolonged or (rarely) permanent effects.

Weight gain affects 20-30% of flunarizine patients and is one of the most common reasons patients discontinue the drug. The average gain is 2-5 kg over the 6-month course, but some patients gain more. The mechanism is primarily H1 antihistamine effect on appetite plus the sedation that reduces activity. Both are addressable with specific strategies.

Patients who gain more than 5 kg during flunarizine use often choose to discontinue, especially if migraine benefit is modest. The cumulative weight gain across multiple 6-month cycles becomes problematic for patients who do multiple courses. Discussing weight as a factor in the restart decision prevents gradual multi-year weight increase from going unnoticed.

Depression is the most serious psychiatric side effect of flunarizine and requires active monitoring throughout treatment. Unlike weight gain which develops visibly, depression can creep in gradually and be rationalized away — "I am just tired," "it has been a stressful month," "work has been bad." Structured monitoring catches it when intervention is still simple.

If depression emerges during flunarizine use, the standard approach is: discontinue flunarizine immediately, consult the prescriber promptly for guidance, consider standard depression treatment (therapy, SSRI when appropriate) during the resolution period, and document this experience as a reason not to restart flunarizine in future cycles. Depression that emerged on flunarizine is a specific contraindication to future flunarizine use.

Extrapyramidal symptoms (EPS) are the most serious neurological side effect of flunarizine. They occur in 3-8% of patients, more commonly in older adults and with longer treatment duration. Early recognition is essential because late-onset movement disorders may be irreversible even after the drug is stopped. The 6-month treatment limit exists specifically because of EPS risk.

If any EPS symptom appears, the appropriate response is: stop flunarizine immediately (not next week, not after talking to the doctor — now), contact the prescriber the same day, and seek neurological evaluation if symptoms persist. Early stopping almost always leads to full resolution over weeks. Continued use after symptoms appear is the main risk factor for persistent movement disorders.

Driving on flunarizine requires specific caution because sedation is the most common side effect, affecting 40-50% of patients. The evening dosing minimizes daytime impact for most patients, but residual morning drowsiness, afternoon fatigue, and interactions with other sedating substances can still affect driving ability. Understanding the risk pattern enables safe operation.

Combining flunarizine with other sedating substances amplifies drowsiness significantly. Alcohol, benzodiazepines, opioids, sedating antihistamines, and sleep aids all stack with flunarizine's effect. Any new sedating medication requires reassessment of driving safety. The combined effect can be much more impairing than either substance alone.

Patients who find daytime drowsiness persistent beyond 2-3 weeks should discuss timing or dose adjustment with the prescriber. Earlier evening dosing (right at bedtime rather than hours before) can shift the sedation into the sleep window. Lower doses (5 mg instead of 10 mg) also reduce sedation. If adjustments do not help, flunarizine may not be the right preventive for this patient.

Older adults using flunarizine require specific caution because the risk of extrapyramidal effects and depression is significantly higher after age 65. The aging dopamine system is more vulnerable to blockade. Most migraine specialists prefer alternative preventives in patients over 65 and strongly consider switching patients who age into this range during use.

The reasons for avoiding flunarizine in older patients are specific and well-studied. The aging dopamine system has reduced neuronal reserves, meaning the same degree of D2 blockade produces more clinical EPS. Older patients also have higher baseline risk of depression, which flunarizine can precipitate. And older patients often have polypharmacy that increases interaction risk.

For older patients who do use flunarizine (because alternatives are unavailable or ineffective), the regimen should be strictly conservative: 5 mg maximum dose, monthly in-person review, formal EPS screening at each visit (using a tool like the AIMS scale), partner awareness and reporting, and willingness to stop at the first sign of problems. The 6-month maximum applies as always.

For migraine starting after age 50 — a different clinical scenario — a thorough workup is appropriate before any preventive is considered. New headache onset in this age group should be worked up for secondary causes (temporal arteritis, intracranial lesion, cervicogenic headache) rather than assumed to be newly presenting migraine.

Flunarizine has one of the better pediatric evidence bases among migraine preventives — studies have shown efficacy and acceptable tolerability in children and adolescents aged 10 and older. For pediatric migraine where lifestyle measures and acute therapy have been insufficient, flunarizine is a reasonable preventive choice, though the same side-effect concerns apply with age-appropriate vigilance.

Pediatric monitoring is especially important because children may not report side effects spontaneously. Parents should check on mood, energy, school performance, weight, and any new movements. Adolescents with frequent migraine have elevated rates of depression and anxiety, and flunarizine own depression risk layers onto this baseline. Any mood decline requires immediate discontinuation and mental health evaluation.

Flunarizine primary interaction concerns are with other sedating substances and other dopamine-blocking drugs. Alcohol, benzodiazepines, sedating antihistamines, opioids, and sleep medications all stack with flunarizine sedation. Antipsychotics, prochlorperazine, and metoclopramide add to its D2 blockade and significantly raise EPS risk.

Flunarizine has a distinct secondary use for vestibular disorders — vertigo, Meniere disease, and vestibular migraine. In patients with both migraine and vestibular symptoms, flunarizine addresses both conditions with the same prescription. This dual indication is one of the drug clinical strengths.

For patients with vestibular migraine specifically — where migraine attacks include prominent vertigo lasting minutes to hours — flunarizine has one of the strongest evidence bases among preventives. The attack frequency reduction tends to be particularly good in this subgroup, often 50-70% in responders.

Flunarizine helps central and migrainous vertigo but does not help peripheral vestibular problems like benign positional vertigo (treated with physical repositioning maneuvers) or vestibular neuritis (resolves with time and physical therapy). Using flunarizine for the wrong vestibular diagnosis wastes the 6-month exposure. ENT or neurology-otology evaluation is often valuable before starting flunarizine for vestibular indications.

Alcohol has particular concern during flunarizine treatment because of significant interaction with sedation. Even modest drinking can produce substantial impairment when combined with flunarizine. The practical rule: minimize alcohol throughout the 6-month course, and avoid alcohol entirely in the hours around the evening dose. For patients who drink socially, early-day light drinking is less problematic than evening drinking that overlaps with the drug peak sedation. Zero alcohol if driving. Patients with known alcohol-triggered migraines also benefit from eliminating alcohol for both the trigger avoidance and the sedation stacking concerns.

Patients using flunarizine should inform surgeons and anesthesiologists at pre-operative assessments. Standard post-operative antiemetics like metoclopramide, prochlorperazine, and droperidol are dopamine blockers that stack with flunarizine D2 blockade. The combination raises risk of EPS including acute dystonic reactions. Anesthesia teams should be explicitly informed about flunarizine so they can choose ondansetron for post-op nausea instead. For elective procedures, there is usually no need to stop flunarizine beforehand — the long half-life means stopping a few days before would not meaningfully reduce drug effect.

Flunarizine should be stored at room temperature (20-25°C) away from excessive heat, moisture, and direct light. Standard medicine cabinet or bedside storage is fine. For travel: carry in carry-on luggage, bring prescription copy, keep original labeling. The long half-life makes small daily timing adjustments reasonable for time zone shifts. For international travel, the drug is widely available in Europe, Asia, Latin America, and Canada but not approved in the United States. Travel to the US with flunarizine prescription is legal for personal use but refilling locally is not possible. Carry enough supply for the full trip plus margin.

Flunarizine overdose is uncommon. Warning signs include severe drowsiness affecting consciousness, agitation paradoxically with sedation, severe weakness, significant tremor or involuntary movements, severe hypotension, confusion. The long half-life means overdose effects can be prolonged — days to weeks rather than hours. Supportive care may need to continue for an extended period. There is no specific antidote. Prevention: safe medication practices, pill organizer, phone reminders, household awareness that others should not take this medication.

Emergency department for thoughts of self-harm or suicide, severe depression, severe tremor or stiffness, acute dystonic reaction, severe allergic reaction, serotonin syndrome signs, loss of consciousness, suspected overdose. Same-day prescriber call for persistent low mood over 2 weeks, new tremor or stiffness, significant weight gain (over 5 kg), severe daytime sedation, breast discharge (women), any involuntary movements, starting new antipsychotic, pregnancy confirmation. Next scheduled visit for attack frequency assessment, mild weight changes, dose adjustment questions, trigger patterns, travel planning, approaching month-6 decision.

The two most serious flunarizine side effects — new depression and extrapyramidal movements — both deteriorate with continued drug exposure. Both call for same-day or same-week contact and almost always lead to drug discontinuation. Early action produces full recovery; delayed action can produce persistent problems.

Flunarizine is contraindicated in: current or history of significant depression; Parkinson disease; any extrapyramidal disorder; tardive dyskinesia (prior or current); family history of early-onset parkinsonism; current antipsychotic therapy; pregnancy; breastfeeding; severe hepatic impairment; known hypersensitivity to flunarizine or cinnarizine; age over 75 (relative; strongly preferred to avoid).

Caution: age 65-74, history of essential tremor, significant obesity, family history of depression, multiple sedating medications, commercial driving occupation, cognitive concerns at baseline, prior migraine preventive non-response.

For patients with contraindications, modern alternatives provide excellent options: CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab), candesartan, beta-blockers, topiramate. The depression contraindication is the one patients and prescribers both tend to underweight — any history of significant depression should be treated as an absolute contraindication regardless of how long ago it was.